Cambridge, Massachusetts-based Third Harmonic did not set any financial terms for the stock sale outlined in the preliminary IPO paperwork filed with regulators on Tuesday. However, IPO research firm ...

Management to hold conference call/webcast today Tuesday, February 11, 2025, at 8:00 a.m. EST to discuss clinical results and corporate next steps SAN FRANCISCO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- ...

Third Harmonic Bio is braving the frosty IPO waters. With the weakest quarter for biotech IPOs in years still fresh in the memory, and the proceeds of a $105 million series B still in its bank account ...

Not only has Third Harmonic pulled off a stock sale, but it was also able to boost the deal size. Wednesday evening, the biotech offered 10.9 million shares priced at $17 each, which was the midpoint ...

Third Harmonic Bio, Inc. (THRD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

The latest price target for Third Harmonic Bio (NASDAQ:THRD) was reported by Stifel on March 28, 2025. The analyst firm set a price target for $5.00 expecting THRD to fall to within 12 months (a ...

CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for ...

Third Harmonic Bio discontinuing its chronic inducible urticaria program after its only asset failed in a phase 1 safety trial paralyzes its clinical pipeline. Shareholders are now waiting on a ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Third Harmonic Bio, a clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for the treatment of severe allergy and inflammation, ...

Third Harmonic Bio has launched from stealth mode with $155 million to develop a single therapy that the Cambridge startup hopes can treat multiple diseases caused by severe allergies and inflammation ...